Pfizer Signs On For Sangamo’s Hemophilia A Gene Therapy
Pfizer has turned again to external expertise among US biotechs to find a potential gene therapy for hemophilia A, to add to its two-year collaboration with Spark Therapeutics on a gene therapy for hemophilia B, and beating off strong competition from other suitors in the process.
You may also be interested in...
Pfizer Advances Duchenne Drug As It Prioritizes Gene Therapy
High value deal with Bamboo Therapeutics starts to come to fruition with start of small study in Duchenne muscular dystrophy, which aims at underlying cause as opposed to symptoms of disease.
Pfizer’s Goettler On What Partners Look For In Orphan Drug Deals
Michael Goettler, Pfizer's global president, rare disease global innovative pharma business, offers tips to Korean orphan drug developers on reaching out to potential partners successfully and what Pfizer is looking for in rare disease deals.
Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.